VM-26 in colorectal carcinoma: A Southwest Oncology Group study

Abstract

In this multi-institutional phase II study, VM-26 or Teniposide was administered to forty-two patients with advanced colorectal cancer. Patients were initially treated at 60 mg/M 2 daily for 5 days with dose adjustments depending on toxicity. One complete response and one partial response were observed lasting six and four months respectively. Leukopenia was severe in 40% of patients. No drug related deaths were seen. In this Southwest Oncology Group (SWOG) study, VM-26 appeared to have minimal benefit in advanced colorectal cancer.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/45328/1/10637_2004_Article_BF00216931.pd